Skip to main content

Qiagen Value Stock - Dividend - Research Selection

Qiagen

ISIN: NL0012169213 , WKN: A2DKCH

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Qiagen N.V. (QGEN) Launches QIAseq xHYB Panels for Long-Read Sequencing

2025-09-11
In this article, we will be taking a look at the 7 Hot Healthcare Stocks to Buy Right Now. Qiagen N.V. is placed seventh among them. Qiagen N.V. (NYSE:QGEN), a global leader in molecular diagnostics and sample preparation technologies, continues to advance its position in clinical laboratories, biopharmaceuticals, and life science research. Headquartered in the […]

QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio

2025-09-10
VENLO, Netherlands, September 10, 2025--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has achieved CE-IVDR certification for its full portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis (ME) Panel that sets a new benchmark in the diagnosis of central nervous system (CNS) infections.

Qiagen N.V. (QGEN) Presents At Baird Global Healthcare Conference 2025 Transcript

2025-09-10
Get the latest on Qiagen's double-digit growth, new diagnostic platforms, and 2026

Hologic's 2025 Outlook Improves on Strong Q3, Easing Tariff Headwinds

2025-09-10
HOLX lifts its 2025 revenue and EPS outlook on Q3 strength, tariff relief, and growth across Breast Health and GYN Surgical.

Qiagen N.V. (QGEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

2025-09-09
Get key insights from QIAGEN's 2025 Healthcare Conference. Explore growth drivers

Investors in Qiagen (NYSE:QGEN) have unfortunately lost 4.9% over the last five years

2025-09-04
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise

2025-09-03
QGEN announces the launch of FDA-cleared QIAstat-Dx Rise, which may boost U.S. diagnostic access and testing capacity worldwide.

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

2025-09-02
GERMANTOWN, Md. & VENLO, Netherlands, September 02, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with the easiest workflow available to customers worldwide.

The Role of M&A in Hologic's Growth Story: Are More Deals in Sight?

2025-08-29
HOLX fuels growth with targeted M&A across Diagnostics, Breast Health, and GYN Surgical, backed by a strong balance sheet.

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds

2025-08-28
VENLO, Netherlands, August 28, 2025--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE.